Comparative Pharmacology
Head-to-head clinical analysis: PIPERACILLIN AND TAZOBACTAM versus SPECTROBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIPERACILLIN AND TAZOBACTAM versus SPECTROBID.
PIPERACILLIN AND TAZOBACTAM vs SPECTROBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), while tazobactam is a beta-lactamase inhibitor that protects piperacillin from degradation by beta-lactamases.
Spectrobird (bacampicillin) is a prodrug of ampicillin, a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours, or 4.5 g (piperacillin 4 g + tazobactam 0.5 g) IV every 8 hours for nosocomial pneumonia.
400 mg orally twice daily or 200 mg orally four times daily for 10-14 days. For acute exacerbations of chronic bronchitis: 400 mg orally twice daily for 10 days.
None Documented
None Documented
Piperacillin ~0.7–1.2 h, tazobactam ~0.7–1.5 h; prolonged in renal impairment (piperacillin up to 3.3 h, tazobactam up to 5.6 h in severe impairment).
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged to 6-10 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal: piperacillin ~68% unchanged, tazobactam ~80% unchanged; biliary excretion <10%; fecal <1%.
Renal: ~75-85% unchanged drug; fecal/biliary: ~15-25% as metabolites and unchanged drug.
Category C
Category C
Penicillin Antibiotic / Beta-Lactamase Inhibitor Combination
Penicillin Antibiotic